+35,195.9%
PAYX vs GSK
+1,641.8%
+33,554.1%
-64.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.4% | -1.0% | +1.4% | +0.7% |
| 7D | -7.9% | -5.4% | -2.5% | -6.3% |
| 30D | -5.0% | -4.6% | -0.4% | -3.7% |
| 3M | +15.1% | -5.1% | +20.2% | +16.8% |
| 6M | +23.9% | -11.4% | +35.4% | +28.0% |
| YTD | +6.2% | +0.7% | +5.5% | +4.8% |
| 1Y | -9.6% | +23.0% | -32.7% | -16.7% |
| 3Y | +5.8% | +48.0% | -42.1% | -9.6% |
| 5Y | +22.0% | +48.2% | -26.3% | +2.6% |
| 10Y | +165.1% | +80.0% | +85.1% | +108.9% |
| All | +35,195.9% | +1,641.8% | +33,554.1% | +15,171.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling